الفهرس 
B-cell Acute Lymphoblastic Leukemia (B-ALL)Only 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
Acute lymphoblastic leukemia is a malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood, and extramedullary sites, with more than 75% originating from B-linage (B-ALL). Unlike pediatric ALL, which is curable in more than 90% of cases, adult ALL has historically had a dismal prognosis, with limited therapy strategies and cure rates less than 40%, due in part to higher-risk disease features in this population and significant chemotherapy-related toxicity. Long noncoding RNAs are defined as transcribed RNA molecules greater than 200 nucleotides in length that are not translated into a protein. Many studies have demonstrated that lncRNAs regulate many biological processes, such as transcription, translation, cellular differentiation, gene expression regulation, and cell cycle regulation. Increasing evidence has revealed that lncRNAs are abnormally expressed in human cancers, suggesting that lncRNAs may act as tumor suppressors or oncogenes. A well-known lncRNA GAS5 has recently become the focus of research attention. Previous studies have reported GAS5 as a novel tumor-suppressor lncRNA which is downregulated in various types of cancer including gastric cancer, lung cancer, hepatocellular carcinoma, and renal cancer. The level of GAS5 expression regulates apoptosis, proliferation, invasion, and metastasis of cancer cells. The discovery of GAS5 has provided a new hope to cancer patients as it may represent a promising prognostic biomarker and a potential therapeutic target. The aim of our study was to investigate the expression level of GAS5 in adult patients with B-ALL and its correlation with clinical outcome and response to therapy during remission induction phase.